Peptide deformylase inhibitors

1. A compound according to Formula (1):

wherein:

R is selected from the group consisting of:

C 2-6 alkyl (optionally substituted by alkoxy, halogen, or C 1-3 alkylsulfanyl); (CH 2 ) n —C 3-6 carbocycle (optionally substituted by alkoxy, halogen, or C 1-3 alkylsulfanyl); and (CH 2 ) n —R2, wherein R2 is selected from the group consisting of phenyl, furan, benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4-benzodioxane or benzo[1,3]dioxole; R2 is optionally substituted by one or more substituent selected from Cl, Br, I, C 1-3 alkyl (optionally substituted by one to three F) and C 1-2 alkoxy (optionally substituted by one to three F)};

R1 is selected from the group consisting of aryl and heteroaryl;

Y represents CH 2 or a covalent bond; and

n is an integer from 0 to 2;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , with the following absolute configuration:

or a pharmaceutically acceptable salt thereof.

3. A compound selected from the group consisting of:

Quinoline-8-carboxylic acid ((R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide;

1,2,3,4-Tetrahydro-quinoline-8-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide;

Benzofuran-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide;

Quinoline-6-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide;

1,2,3,4-Tetrahydro-quinoline-6-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide;

2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoyl]amino}-methyl)-amide;

7-Methoxy-benzofuran-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide;

5-Methoxy-benzofuran-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide;

3,4-Dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide;

5-Trifluoromethyl-furan-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide;

3,4-Difluoro-N-({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl )-benzamide;

2,3-Difluoro-N-({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl )-benzamide;

[1,8]Naphthyridine-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide;

3-Methyl-benzofuran-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide;

Benzo[1,3]dioxole-5-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide;

Benzofuran-2-carboxylic acid {[(R)-2-cyclopentylmethyl-3-(formyl-hydroxy-amino)-propanoylamino]-methyl}-amide; and

Benzofuran-2-carboxylic acid ({(R)-7,7,7-trifiuoro-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide; or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a compound according claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

5. A pharmaceutical composition comprising a compound according claim 3 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.